Holistic Financial Partners Sells 1,834 Shares of Merck & Co., Inc. $MRK

Holistic Financial Partners trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 41.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,575 shares of the company’s stock after selling 1,834 shares during the quarter. Holistic Financial Partners’ holdings in Merck & Co., Inc. were worth $204,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Vanguard Group Inc. increased its position in Merck & Co., Inc. by 0.6% during the first quarter. Vanguard Group Inc. now owns 252,513,381 shares of the company’s stock worth $22,665,601,000 after acquiring an additional 1,417,274 shares during the period. Wellington Management Group LLP grew its stake in Merck & Co., Inc. by 1.1% during the first quarter. Wellington Management Group LLP now owns 81,669,651 shares of the company’s stock worth $7,330,668,000 after buying an additional 927,621 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Merck & Co., Inc. by 144.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 49,229,283 shares of the company’s stock worth $4,418,820,000 after buying an additional 29,104,112 shares in the last quarter. Amundi grew its stake in Merck & Co., Inc. by 37.1% during the first quarter. Amundi now owns 13,077,716 shares of the company’s stock worth $1,130,397,000 after buying an additional 3,542,036 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in Merck & Co., Inc. during the first quarter worth about $991,553,000. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Trading Down 4.0%

MRK opened at $82.51 on Tuesday. The company’s 50 day moving average is $84.51 and its 200-day moving average is $81.89. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $105.07. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. The company has a market cap of $206.09 billion, a P/E ratio of 12.71, a PEG ratio of 0.95 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, October 30th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.36 by $0.22. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The company had revenue of $17.28 billion for the quarter, compared to the consensus estimate of $17 billion. During the same period last year, the company posted $1.57 EPS. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. Equities research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on MRK shares. Morgan Stanley increased their price objective on shares of Merck & Co., Inc. from $98.00 to $100.00 and gave the stock an “equal weight” rating in a research note on Monday. Wells Fargo & Company reduced their price objective on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 30th. Citigroup started coverage on shares of Merck & Co., Inc. in a research note on Monday, October 13th. They set a “neutral” rating and a $95.00 price objective on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Finally, Berenberg Bank downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $100.00 to $90.00 in a research note on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Hold” and a consensus target price of $104.47.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.